Status:
COMPLETED
Therapeutic Adherence in Uncontrolled Arterial Hypertension
Lead Sponsor:
Parc de Salut Mar
Collaborating Sponsors:
Fondo de Investigacion Sanitaria
Conditions:
Treatment Adherence
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In hypertension, highly prevalent, up to 10-15% of hypertensive patients have uncontrolled blood pressure despite being treated with ≥3 drugs, which is known as resistant hypertension. Resistant arter...
Detailed Description
Objective: To assess whether the implementation of a specific action plan to improve adherence for 3 months results in reduced peripheral 24h-systolic blood pressure (SBP) in patients with resistant h...
Eligibility Criteria
Inclusion
- patients aged ≥18 years
- diagnosis of resistant hypertension with treatment superior to 3 drugs at maximum dose, one of them being a diuretic
- uncontrolled hypertension treated with 2 drugs at the maximum effective doses tolerated
- the prescribed treatment must be stable for the last 2 months
- given informed consent
Exclusion
- secondary arterial hypertension
- pregnant women
- Impossibility to perform a 24-hour blood pressure monitoring, or poor quality results.
- Recent history of major vascular episode
- patients receiving treatment with Barnidipino / Felodipine / Lercanidipine / Manidipine / Nifedipine / Verapamil / Eplerenone
Key Trial Info
Start Date :
July 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT04464746
Start Date
July 1 2018
End Date
December 31 2023
Last Update
June 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital del Mar
Barcelona, Spain, 08003